Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04LBC
|
|||
| Former ID |
DCL000840
|
|||
| Drug Name |
Iclaprim
|
|||
| Synonyms |
192314-93-5; AR-100; 5-[(2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-yl)methyl]pyrimidine-2,4-diamine; RO-48-2622; Mersarex; 5-((2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl)pyrimidine-2,4-diamine; Iclaprim [USAN:INN]; Iclaprim (USAN/INN); 2,4-Pyrimidinediamine, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-; 2,4-Pyrimidinediamine, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-; AR 100; AC1Q4WM5; SCHEMBL379386; CHEMBL134561; AC1L4U54; SCHEMBL12899446; CTK4E0971; BDBM18070; Iclaprim [INN]; AR-102; AR-100001; 5-((2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)pyrimidine-2,4-diamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 3 | [1] | |
| Pneumonia [ICD-11: CA40] | Phase 2 | [2] | ||
| Acute bacterial skin infection [ICD-11: 1C41] | Application submitted | [3] | ||
| Company |
Arpida
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H22N4O3
|
|||
| Canonical SMILES |
COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC
|
|||
| InChI |
1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)
|
|||
| InChIKey |
HWJPWWYTGBZDEG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 192314-93-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:131751
|
|||
| SuperDrug ATC ID |
J01EA03
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Dihydrofolate reductase (Bact DHFR) | Target Info | Modulator | [4] |
| Dihydrofolate reductase (DHFR) | Target Info | Inhibitor | [3] | |
| Prostaglandin receptor (PTGR) | Target Info | Modulator | [5] | |
| KEGG Pathway | One carbon pool by folate | |||
| Folate biosynthesis | ||||
| Metabolic pathways | ||||
| Panther Pathway | Tetrahydrofolate biosynthesis | |||
| Formyltetrahydroformate biosynthesis | ||||
| Pathwhiz Pathway | Folate Metabolism | |||
| Pterine Biosynthesis | ||||
| Pathway Interaction Database | E2F transcription factor network | |||
| Reactome | E2F mediated regulation of DNA replication | |||
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | ||||
| Metabolism of folate and pterines | ||||
| G1/S-Specific Transcription | ||||
| WikiPathways | Nucleotide Metabolism | |||
| Trans-sulfuration and one carbon metabolism | ||||
| Retinoblastoma (RB) in Cancer | ||||
| One Carbon Metabolism | ||||
| Metabolism of water-soluble vitamins and cofactors | ||||
| Metabolism of nitric oxide | ||||
| Folate Metabolism | ||||
| Fluoropyrimidine Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. | |||
| REF 2 | ClinicalTrials.gov (NCT00523250) Ocular Hypotensive Efficacy of AR-102. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.Future Microbiol.2009 Mar;4(2):131-44. | |||
| REF 5 | Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.